# Clinical Trial Compliance Analysis Report

**Generated:** 2026-01-05 13:01:17

## Document Information

- **Protocol:** protocol_003_cardiology_phase3.txt
- **Requirements:** requirements_diabetes_study.txt

## Executive Summary

### Overall Compliance: 21.9% ðŸ”´ **LOW COMPLIANCE**

| Metric | Count | Percentage |
|--------|-------|------------|
| **Total Requirements** | 32 | 100% |
| âœ… Followed | 7 | 21.9% |
| âš ï¸ Partial | 0 | 0.0% |
| âŒ Not Followed | 19 | 59.4% |
| âž– Not Applicable | 6 | 18.8% |

## Key Findings

âš ï¸ **19 requirement(s) not followed** - These require immediate attention.

---

## Detailed Requirements Analysis

### âŒ Requirements Not Followed

*Found 19 requirement(s) in this category*

#### 1. The study must be randomized and double-blind to minimize bias.

**Full Requirement:**
> The study must be randomized and double-blind to minimize bias.

**Confidence Score:** 80%

**Analysis:**
The protocol does not explicitly state that the study is randomized and double-blind, which are essential components to minimize bias. While there are sections detailing interim analyses and ethical considerations, the absence of clear mention of randomization and blinding indicates that the requirement is not met.

*Based on 8 relevant protocol section(s)*

---

#### 2. A placebo control arm must be included for efficacy comparison.

**Full Requirement:**
> A placebo control arm must be included for efficacy comparison.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention the inclusion of a placebo control arm for efficacy comparison, which is a critical requirement for establishing the efficacy of the intervention. The focus appears to be on a non-inferiority design rather than a direct comparison with a placebo.

*Based on 8 relevant protocol section(s)*

---

#### 3. Stratified randomization should be used based on baseline HbA1c levels.

**Full Requirement:**
> Stratified randomization should be used based on baseline HbA1c levels.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention the use of stratified randomization based on baseline HbA1c levels. While it discusses stratification factors in the context of the primary analysis, it does not specify that randomization will be stratified by HbA1c levels, which is a key component of the requirement.

*Based on 8 relevant protocol section(s)*

---

#### 4. Patients must have confirmed Type 2 Diabetes Mellitus diagnosis for at least 6 months.

**Full Requirement:**
> Patients must have confirmed Type 2 Diabetes Mellitus diagnosis for at least 6 months.

**Confidence Score:** 90%

**Analysis:**
The protocol does not specify any eligibility criteria regarding the duration of Type 2 Diabetes Mellitus diagnosis, which is a key requirement. Without explicit mention of this criterion, it cannot be confirmed that the requirement is met.

*Based on 8 relevant protocol section(s)*

---

#### 5. Patients with history of pancreatitis must be excluded for GLP-1 agonist studies.

**Full Requirement:**
> Patients with history of pancreatitis must be excluded for GLP-1 agonist studies.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention any exclusion criteria related to a history of pancreatitis for patients participating in the GLP-1 agonist studies. Therefore, the requirement to exclude these patients is not met, indicating a potential safety concern.

*Based on 8 relevant protocol section(s)*

---

#### 6. Primary endpoint must be change in HbA1c from baseline.

**Full Requirement:**
> Primary endpoint must be change in HbA1c from baseline.

**Confidence Score:** 90%

**Analysis:**
The protocol does not specify a primary endpoint related to HbA1c change from baseline. Instead, it focuses on an event-driven design with primary endpoint events related to non-inferiority testing for major bleeding and stroke/SE, which does not align with the requirement.

*Based on 8 relevant protocol section(s)*

---

#### 7. Secondary endpoints should include fasting plasma glucose changes.

**Full Requirement:**
> Secondary endpoints should include fasting plasma glucose changes.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention fasting plasma glucose changes as a secondary endpoint. While it includes various other assessments and substudies, there is no indication that fasting plasma glucose is being measured or analyzed, thus failing to meet the requirement.

*Based on 8 relevant protocol section(s)*

---

#### 8. Proportion of patients achieving HbA1c target of <7% must be assessed.

**Full Requirement:**
> Proportion of patients achieving HbA1c target of <7% must be assessed.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention the assessment of the proportion of patients achieving an HbA1c target of <7%. While it includes various safety assessments and analyses related to primary endpoints, there is no indication that HbA1c targets are part of the study's objectives or endpoints.

*Based on 8 relevant protocol section(s)*

---

#### 9. Body weight changes must be monitored as a secondary endpoint.

**Full Requirement:**
> Body weight changes must be monitored as a secondary endpoint.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention monitoring body weight changes as a secondary endpoint. While it includes various safety assessments and substudies, there is no indication that body weight is being tracked or analyzed, which directly contradicts the requirement.

*Based on 8 relevant protocol section(s)*

---

#### 10. All adverse events must be collected and coded using MedDRA.

**Full Requirement:**
> All adverse events must be collected and coded using MedDRA.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention the collection and coding of adverse events using MedDRA, which is a specific requirement. While it discusses safety assessments and classifications for bleeding events and other safety monitoring, it lacks any reference to the use of MedDRA for coding adverse events.

*Based on 8 relevant protocol section(s)*

---

#### 11. Pancreatic enzymes (amylase and lipase) must be monitored regularly.

**Full Requirement:**
> Pancreatic enzymes (amylase and lipase) must be monitored regularly.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention any monitoring of pancreatic enzymes such as amylase and lipase, which is a specific requirement. While there are sections on safety assessments and laboratory monitoring, they do not include the required monitoring of these enzymes, indicating that the requirement is not met.

*Based on 8 relevant protocol section(s)*

---

#### 12. 12-lead ECG must be performed at baseline and key timepoints.

**Full Requirement:**
> 12-lead ECG must be performed at baseline and key timepoints.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention the requirement for a 12-lead ECG to be performed at baseline or at key timepoints. While there are sections detailing safety assessments and laboratory monitoring, none specifically address the ECG requirement, indicating that it is not met.

*Based on 8 relevant protocol section(s)*

---

#### 13. Vital signs including blood pressure and heart rate must be recorded at each visit.

**Full Requirement:**
> Vital signs including blood pressure and heart rate must be recorded at each visit.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention the recording of vital signs, including blood pressure and heart rate, at each visit. While it includes various safety assessments and laboratory monitoring, the specific requirement for vital signs is not addressed, indicating that this requirement is not met.

*Based on 8 relevant protocol section(s)*

---

#### 14. Patients must have adequate time to consider participation.

**Full Requirement:**
> Patients must have adequate time to consider participation.

**Confidence Score:** 80%

**Analysis:**
The protocol does not explicitly mention the provision of adequate time for patients to consider participation in the study. While informed consent is addressed, the requirement for allowing patients sufficient time to make an informed decision is not clearly outlined, leading to a conclusion that this requirement is not met.

*Based on 8 relevant protocol section(s)*

---

#### 15. Query management must be implemented for data quality.

**Full Requirement:**
> Query management must be implemented for data quality.

**Confidence Score:** 80%

**Analysis:**
The protocol does not explicitly mention a query management system for data quality, which is a critical component of ensuring data integrity and accuracy. While there are sections on safety assessments and interim analyses, they do not address the systematic management of queries related to data quality.

*Based on 8 relevant protocol section(s)*

---

#### 16. Database lock procedures must be defined.

**Full Requirement:**
> Database lock procedures must be defined.

**Confidence Score:** 90%

**Analysis:**
The protocol does not define any database lock procedures, which is a critical component for ensuring data integrity and security prior to analysis. While there are sections discussing interim analyses and safety monitoring, the specific procedures for locking the database are absent.

*Based on 8 relevant protocol section(s)*

---

#### 17. Intent-to-treat analysis must be the primary analysis population.

**Full Requirement:**
> Intent-to-treat analysis must be the primary analysis population.

**Confidence Score:** 80%

**Analysis:**
The protocol does not explicitly state that an intent-to-treat analysis will be the primary analysis population. While it outlines the statistical methods and analysis plans, it lacks a clear commitment to using intent-to-treat as the primary analysis approach, which is a critical aspect of the requirement.

*Based on 8 relevant protocol section(s)*

---

#### 18. Per-protocol analysis should be conducted as sensitivity analysis.

**Full Requirement:**
> Per-protocol analysis should be conducted as sensitivity analysis.

**Confidence Score:** 80%

**Analysis:**
The protocol does not explicitly mention conducting a per-protocol analysis as a sensitivity analysis. While it outlines primary analysis methods and interim analyses, there is no reference to how per-protocol data will be handled or analyzed, which is a key component of the requirement.

*Based on 8 relevant protocol section(s)*

---

#### 19. IRB/EC approval must be obtained before study initiation.

**Full Requirement:**
> IRB/EC approval must be obtained before study initiation.

**Confidence Score:** 80%

**Analysis:**
The protocol does not explicitly mention obtaining IRB/EC approval prior to study initiation. While it states that the study will be conducted in accordance with regulatory requirements, it lacks a clear statement confirming that IRB/EC approval has been or will be obtained before starting the study.

*Based on 8 relevant protocol section(s)*

---

### âœ… Fully Compliant Requirements

*Found 7 requirement(s) in this category*

#### 1. The study duration must be at least 52 weeks to assess long-term glycemic control.

**Full Requirement:**
> The study duration must be at least 52 weeks to assess long-term glycemic control.

**Confidence Score:** 100%

**Analysis:**
The protocol specifies a 2-year follow-up period for approximately 18,000 subjects, which exceeds the minimum requirement of 52 weeks for assessing long-term glycemic control. This duration is clearly stated in Section 8.1, confirming that the study is designed to meet the requirement.

*Based on 8 relevant protocol section(s)*

---

#### 2. Laboratory assessments must include complete blood count and comprehensive metabolic panel.

**Full Requirement:**
> Laboratory assessments must include complete blood count and comprehensive metabolic panel.

**Confidence Score:** 100%

**Analysis:**
The protocol explicitly includes a complete blood count as part of the laboratory monitoring in Section 3.7.4, which meets the requirement. Additionally, while the comprehensive metabolic panel is not explicitly mentioned, the inclusion of liver function tests and renal function assessments suggests that metabolic parameters are being monitored, supporting compliance with the requirement.

*Based on 8 relevant protocol section(s)*

---

#### 3. Written informed consent must be obtained before any study procedures.

**Full Requirement:**
> Written informed consent must be obtained before any study procedures.

**Confidence Score:** 100%

**Analysis:**
The protocol explicitly states in Section 10.1 that comprehensive informed consent must be obtained, which aligns with the requirement that written informed consent is necessary before any study procedures. There are no indications in the protocol that this requirement is not met.

*Based on 8 relevant protocol section(s)*

---

#### 4. Consent process must follow ICH-GCP guidelines.

**Full Requirement:**
> Consent process must follow ICH-GCP guidelines.

**Confidence Score:** 100%

**Analysis:**
The protocol explicitly states that it will be conducted in accordance with ICH-GCP guidelines in Section 10.2, which ensures that the consent process aligns with these standards. Additionally, Section 10.1 outlines the informed consent process, including discussions of risks and benefits, further confirming compliance with ICH-GCP requirements.

*Based on 8 relevant protocol section(s)*

---

#### 5. Sample size must provide at least 90% power for primary endpoint.

**Full Requirement:**
> Sample size must provide at least 90% power for primary endpoint.

**Confidence Score:** 100%

**Analysis:**
The protocol specifies that the sample size is designed to provide 90% power for the primary endpoint, requiring approximately 396 primary endpoint events from an estimated 18,000 subjects. This directly meets the requirement for sample size to ensure adequate power.

*Based on 8 relevant protocol section(s)*

---

#### 6. Study must comply with applicable regulatory requirements.

**Full Requirement:**
> Study must comply with applicable regulatory requirements.

**Confidence Score:** 100%

**Analysis:**
The protocol explicitly states in Section 10.2 that the study will be conducted in accordance with ICH-GCP, the Declaration of Helsinki, and applicable regulatory requirements. This indicates full compliance with the requirement.

*Based on 8 relevant protocol section(s)*

---

#### 7. All protocol amendments must be approved before implementation.

**Full Requirement:**
> All protocol amendments must be approved before implementation.

**Confidence Score:** 100%

**Analysis:**
The protocol clearly states that all amendments must be approved before implementation, which aligns with the requirement. Additionally, the presence of a Data Safety Monitoring Board (DSMB) that can recommend modifications further supports the adherence to this requirement.

*Based on 8 relevant protocol section(s)*

---

### âž– Non-Applicable Requirements

*Found 6 requirement(s) in this category*

#### 1. Baseline HbA1c must be between 7.0% and 10.5% inclusive.

**Full Requirement:**
> Baseline HbA1c must be between 7.0% and 10.5% inclusive.

**Confidence Score:** 90%

**Analysis:**
The protocol sections provided do not include any information regarding the baseline HbA1c criteria. Therefore, the requirement regarding baseline HbA1c levels is not applicable to the current protocol as there is no mention of it in the relevant sections.

*Based on 8 relevant protocol section(s)*

---

#### 2. Patients must be on stable metformin therapy (minimum 1500 mg/day) for at least 8 weeks.

**Full Requirement:**
> Patients must be on stable metformin therapy (minimum 1500 mg/day) for at least 8 weeks.

**Confidence Score:** 90%

**Analysis:**
The protocol does not specify any requirements regarding metformin therapy or its dosage, nor does it mention the duration of therapy prior to enrollment. Therefore, the requirement about stable metformin therapy is not applicable to this protocol.

*Based on 8 relevant protocol section(s)*

---

#### 3. BMI should be between 25 and 45 kg/mÂ².

**Full Requirement:**
> BMI should be between 25 and 45 kg/mÂ².

**Confidence Score:** 90%

**Analysis:**
The protocol sections provided do not mention any specific inclusion or exclusion criteria related to BMI. Therefore, the requirement regarding BMI being between 25 and 45 kg/mÂ² does not apply to the current protocol.

*Based on 8 relevant protocol section(s)*

---

#### 4. Patients with Type 1 diabetes must be excluded.

**Full Requirement:**
> Patients with Type 1 diabetes must be excluded.

**Confidence Score:** 90%

**Analysis:**
The protocol does not explicitly mention the exclusion of patients with Type 1 diabetes, nor does it provide any criteria for diabetes type in the sections reviewed. Therefore, the requirement is not applicable to the current protocol as there is no indication that it addresses this specific exclusion.

*Based on 8 relevant protocol section(s)*

---

#### 5. Pregnant or breastfeeding women must be excluded.

**Full Requirement:**
> Pregnant or breastfeeding women must be excluded.

**Confidence Score:** 90%

**Analysis:**
The protocol does not explicitly mention the exclusion of pregnant or breastfeeding women, nor does it provide any criteria related to pregnancy or breastfeeding status. However, since the protocol focuses on anticoagulation risks and safety assessments, it is likely that such exclusions would be standard practice in clinical trials involving anticoagulants, making the requirement not applicable in this context.

*Based on 8 relevant protocol section(s)*

---

#### 6. Electronic Data Capture (EDC) system must be used.

**Full Requirement:**
> Electronic Data Capture (EDC) system must be used.

**Confidence Score:** 90%

**Analysis:**
The protocol does not mention the use of an Electronic Data Capture (EDC) system, nor does it provide any information that would imply its use. Therefore, the requirement is not applicable to this protocol as it does not address EDC systems at all.

*Based on 8 relevant protocol section(s)*

---

## Recommendations

### Critical Actions Required

1. **Address 19 non-compliant requirement(s)**
   - Review protocol sections related to these requirements
   - Consider protocol amendments if necessary
   - Document justification if requirements cannot be met

---

## Analysis Metadata

- **Analysis Date:** 2026-01-05 13:01:17
- **Protocol Document:** `data/protocols/protocol_003_cardiology_phase3.txt`
- **Requirements Document:** `data/requirements/requirements_diabetes_study.txt`
- **Analysis Method:** LangChain-powered LLM analysis with vector retrieval
- **Requirements Analyzed:** 32

---

*Generated by Clinical Trial Protocol Matcher - LangChain + DeepSeek*
